title: Reply to Kevin Lu's Letter to the Editor re: Orazio Caffo, Ugo De Giorgi, Lucia Fratino, et al. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. Eur Urol 2015;68:147-53.
authors: Medical Oncology Department, Santa Chiara Hospital, Trento, Italy. Electronic address: orazio.caffo@apss.tn.it.
authors: Orazio
authors: O
authors: Caffo
authors: Medical Oncology Department, Santa Chiara Hospital, Trento, Italy.
authors: Francesca
authors: F
authors: Maines
authors: Medical Oncology Department, Santa Chiara Hospital, Trento, Italy.
authors: Antonello
authors: A
authors: Veccia
mesh_terms: D000069501:Abiraterone Acetate / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010669:Phenylthiohydantoin / Q000031:analogs & derivatives*; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy*; D043823:Taxoids / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D043823:Taxoids; D010669:Phenylthiohydantoin; D000069501:Abiraterone Acetate